All > Asd > Nuplazid

Pimavanserin for Autism Spectrum Disorder (ASD)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Autism Spectrum Disorder (ASD)Pimavanserin - Drug
Eligibility
5 - 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial is an open-label extension of the double-blind study, which means that all participants will receive pimavanserin for an additional 52 weeks. The purpose of this trial is to determine the long-term safety and tolerability of pimavanserin in this population.

Eligible Conditions
  • Autism Spectrum Disorder (ASD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
RO7303509
1
Pimavanserin
1
Growth Hormone

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 52 weeks

52 weeks
Irritable Mood
Therapeutic procedure

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
RO7303509
2
Pimavanserin
2
Growth Hormone

Side Effects for

Open-label Treatment
33%sleepiness
17%skin irritation
17%weight gain
17%dry mouth
17%headache
17%arthralgia
17%diarrhea
This histogram enumerates side effects from a completed 2021 Phase 4 trial (NCT04188392) in the Open-label Treatment ARM group. Side effects include: sleepiness with 33%, skin irritation with 17%, weight gain with 17%, dry mouth with 17%, headache with 17%.

Trial Design

1 Treatment Group

Pimavanserin
1 of 1

Experimental Treatment

228 Total Participants · 1 Treatment Group

Primary Treatment: Pimavanserin · No Placebo Group · Phase 2 & 3

Pimavanserin
Drug
Experimental Group · 1 Intervention: Pimavanserin · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pimavanserin
2018
Completed Phase 4
~2410

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 52 weeks

Who is running the clinical trial?

ACADIA Pharmaceuticals Inc.Lead Sponsor
40 Previous Clinical Trials
8,710 Total Patients Enrolled

Eligibility Criteria

Age 5 - 18 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have completed the treatment period of study ACP-103-069.
You are female and not pregnant or able to become pregnant.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top